Intelligent Bio Solutions Inc. (INBS)
Healthcare · NCM
Fundamentals
Valuation and ratings
Intelligent Bio Solutions Inc. trades at USD1.79, which is 115% below the USD3.85 our discounted cash flow model puts on the business. On that measure alone it screens as undervalued, though a DCF is an argument rather than a measurement, and the market is frequently right about why something is cheap.
Our moat model scores it 35 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
INBS earnings and analyst estimates
Recommendation mix, 1 analyst rating
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. Intelligent Bio Solutions Inc. was incorporated in 2016 and is headquartered in New York, New York.
INBS passes 3 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Common questions
Is Intelligent Bio Solutions Inc. (INBS) undervalued?
Against our discounted cash flow estimate of USD3.85, INBS at USD1.79 is 115% below fair value. That is one model's answer, not a recommendation, and most of a DCF's output sits in a terminal value nobody can forecast.
The full research page for INBS, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.